Skip to main content
SpringerLink
Log in

Development of Prophylactics and Therapeutics Against the Smallpox and Monkeypox Biothreat Agents

  • Conference paper
National Institute of Allergy and Infectious Diseases, NIH

Part of the book series: Infectious Disease ((ID))

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 259.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 329.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 329.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Buller RML (2004) Poxviruses. Infectious Diseases (Cohen J, PowderlyW, eds.), pp. 2053–2059. Elsevier Ltd, New York.

    Google Scholar 

  2. Damaso CR, Esposito JJ, Condit RC, Moussatche N (2000) An emergent poxvirus from humans and cattle in Rio de Janeiro State: Cantagalo virus may derive from Brazilian smallpox vaccine. Virology 2:439–499.

    Google Scholar 

  3. Kolhapure RM, Deolankar RP, Tupe CD, Raut CG, Basu A, Dama BM, et al (1997) Investigation of buffalopox outbreaks in Maharashtra State during 1992–1996. Ind J Med Res 106:441– 446.

    CAS  Google Scholar 

  4. Baxby D, Bennett M, Getty B (1994) Human cowpox 1969–93: a review based on 54 cases. Br J Dermatol 5:598–607.

    Google Scholar 

  5. Fenner F, Henderson DA, Arita I, Jezek Z, Ladnyj ID (1988) Smallpox and its eradication. World Health Organization, Geneva, Switzerland

    Google Scholar 

  6. Breman JG, Henderson DA (2002) Diagnosis and management of smallpox. N Engl J Med 346:1300–1308.

    PubMed  Google Scholar 

  7. Wehrle PF, Posch J, Richter KH, Henderson DA (1970) An airborne outbreak of smallpox in a German hospital and its significance with respect to other recent outbreaks in Europe. Bull World Health Organ 43:669–679.

    PubMed  CAS  Google Scholar 

  8. Zelicoff AP (2003) An epidemiological analysis of the 1971 smallpox outbreak in Aralsk, Kazakhstan. Crit Rev Microbiol 29:97–108.

    PubMed  Google Scholar 

  9. Jackson RJ, Ramsay AJ, Christensen CD, Beaton S, Hall DF, Ramshaw IA (2001) Expression of mouse interleukin-4 by a recombinant ectromelia virus suppresses cytolytic lymphocyte responses and overcomes genetic resistance to mousepox. J Virol 75:1205–1210.

    PubMed  CAS  Google Scholar 

  10. Parker S, Nuara AA, Buller RML, Schultz DA (2007) Human monkeypox: an emerging zoonotic disease. Future Microbiol 2:17–34.

    PubMed  CAS  Google Scholar 

  11. Jezek Z, Fenner F (1988) Human monkeypox. In: Monographs in Virology, volume 17 MelnickJL, ed.Karger, Basel.

    Google Scholar 

  12. Gispen R, Verlinde JD, Zwart P (1967) Histopathological and virological studies on monkeypox. Arch Gesamte Virusforsch 21:205–216

    PubMed  CAS  Google Scholar 

  13. Mukinda VB, Mwema G, Kilundu M, Heymann DL, Khan AS, Esposito JJ (1997) Re-emergence of human monkeypox in Zaire in 1996. Monkeypox Epidemiologic Working Group[letter]. Lancet 349:1449–1450.

    PubMed  CAS  Google Scholar 

  14. Heymann DL, Szczeniowski M, Esteves K (1998) Re-emergence of monkeypox in Africa: a review of the past six years. Br Med Bull 54:693–702.

    PubMed  CAS  Google Scholar 

  15. Chen N, Li G, Liszewski MK, Atkinson JP, Jahrling PB, Feng Z, et al (2005) Virulence differences between monkeypox virus isolates from West Africa and the Congo basin. Virology 340:46–63.

    PubMed  CAS  Google Scholar 

  16. Likos AM, Sammons SA, Olson VA, Frace AM, Li Y, Olsen-Rasmussen M, et al (2005) A tale of two clades: monkeypox viruses. J Gen Virol 86:2661–2672.

    PubMed  CAS  Google Scholar 

  17. Nalca A, Rimoin AW, Bavari S, Whitehouse CA (2005) Reemergence of monkeypox: prevalence, diagnostics, and countermeasures. Clin Infect Dis 41:1765–1771.

    PubMed  Google Scholar 

  18. Jezek Z, Grab B, Dixon H (1987) Stochastic model for interhuman spread of monkeypox. Am J Epidemiol 126:1082–1092.

    PubMed  CAS  Google Scholar 

  19. Learned LA, Reynolds MG, Wassa DW, Li Y, Olson VA, Karem K, et al (2005) Extended interhuman transmission of monkeypox in a hospital community in the Republic of the Congo, 2003. Am J Trop Med Hyg 73:428–434.

    PubMed  Google Scholar 

  20. Reed KD, Melski JW, Graham MB, Regnery RL, Sotir MJ, Wegner MV, et al (2004) The detection of monkeypox in humans in the Western Hemisphere. N Engl J Med 350:342–350.

    PubMed  CAS  Google Scholar 

  21. Damon IK, Roth CE, Chowdhary V (2006) Discovery of monkeypox in Sudan. N Engl J Med 355:962–963.

    PubMed  CAS  Google Scholar 

  22. Hutin YJ, Williams RJ, Malfait P, Pebody R, Loparev VN, Ropp SL, et al (2001) Outbreak of human monkeypox, Democratic Republic of Congo, 1996 to 1997. Emerg Infect Dis 7:434–488.

    PubMed  CAS  Google Scholar 

  23. Meyer H, Perrichot M, Stemmler M, Emmerich P, Schmitz H, Varaine F, et al (2002) Outbreaks of disease suspected of being due to human monkeypox virus infection in the Democratic Republic of Congo in 2001. J Clin Microbiol 40:2919–2921.

    PubMed  Google Scholar 

  24. Mets T, Ngendahayo P, Van de PP, Mutwewingabo A (1989) HIV infection and tuberculosis in Central Africa. N Engl J Med 321:542–543.

    PubMed  CAS  Google Scholar 

  25. Sonnet J, Prignot J, Zech F, Willame JC (1987) High prevalence of tuberculosis in HIV infected black patients from Central Africa. Ann Soc Belg Med Trop 67:299–300.

    PubMed  CAS  Google Scholar 

  26. Fine PE, Jezek Z, Grab B, Dixon H (1988) The transmission potential of monkeypox virus in human populations. Int J Epidemiol 17:643–650.

    PubMed  CAS  Google Scholar 

  27. Garrett L (1994) The Coming Plague. Farrar, Straus and Giroux, New York

    Google Scholar 

  28. General Accounting Office. (2004) Emerging Infectious Diseases-Review of State and Federal Disease Surveillance Efforts.

    Google Scholar 

  29. Alibek K, Handelman S (1999) Biohazard. Delta, New York.

    Google Scholar 

  30. wikipedia. 2007.

    Google Scholar 

  31. Takahashi H, Keim P, Kaufmann AF, Keys C, Smith KL, Taniguchi K, et al. 2004 Bacillus anthracis incident, Kameido, Tokyo, 1993. Emerg Infect Dis 10:117–120.

    PubMed  Google Scholar 

  32. Frey SE, Couch RB, Tacket CO, Treanor JJ, Wolff M, Newman FK, et al 2002 Clinical responses to undiluted and diluted smallpox vaccine. N Engl J Med 346:1265–1274.

    PubMed  CAS  Google Scholar 

  33. Frey SE, Newman FK, Cruz J, Shelton WB, Tennant JM, Polach T, et al 2002 Dose-related effects of smallpox vaccine. N Engl J Med 346:1275–1280.

    PubMed  CAS  Google Scholar 

  34. Weltzin R, Liu J, Pugachev KV, Myers GA, Coughlin B, Blum PS, et al 2003 Clonal vaccinia virus grown in cell culture as a new smallpox vaccine. Nat Med 9:1125–1130.

    PubMed  CAS  Google Scholar 

  35. Vollmar J, Arndtz N, Eckl KM, Thomsen T, Petzold B, Mateo L, et al 2006 Safety and immunogenicity of IMVAMUNE, a promising candidate as a third generation smallpox vaccine. Vaccine 24:2065–2070.

    PubMed  CAS  Google Scholar 

  36. Meseda CA, Garcia AD, Kumar A, Mayer AE, Manischewitz J, King LR, et al 2005 Enhanced immunogenicity and protective effect conferred by vaccination with combinations of modified vaccinia virus Ankara and licensed smallpox vaccine Dryvax in a mouse model. Virology 339:164–175.

    PubMed  CAS  Google Scholar 

  37. Painter GR, Hostetler KY 2004 Design and development of oral drugs for the prophylaxis and treatment of smallpox infection. Trends Biotechnol 22:423–427.

    PubMed  CAS  Google Scholar 

  38. Yang G, Pevear DC, Davies MH, Collett MS, Bailey T, Rippen S, et al 2005An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus Challenge. J Virol79:13,139–13,149.

    CAS  Google Scholar 

  39. Li G, Chen N, Feng Z, Buller RM, Osborne J, Harms T, et al 2006 Genomic sequence and analysis of a vaccinia virus isolate from a patient with a smallpox vaccine-related complication. Virol J 3:88.

    PubMed  Google Scholar 

  40. Lefkowitz EJ, Upton C, Changayil SS, Buck C, Traktman P, Buller RM 2005 Poxvirus Bioinformatics Resource Center: a comprehensive Poxviridae informational and analytical resource. Nucleic Acids Res33:D311–D316.

    PubMed  CAS  Google Scholar 

  41. Chen N, Li G, Liszewski MK, Atkinson JP, Jahrling PB, Feng Z, et al 2005Virulence differences between monkeypox virus isolates from West Africa and the Congo basin. Virology 340: 46 – 63.

    PubMed  CAS  Google Scholar 

  42. Li G, Chen N, Roper RL, Feng Z, Hunter A, Danila M, et al 2005 Complete coding sequences of the rabbitpox virus genome. J Gen Virol 86:2969–2977.

    PubMed  CAS  Google Scholar 

  43. Chen N, Danila MI, Feng Z, Buller RM, Wang C, Han X, et al 2003 The genomic sequence of ectromelia virus, the causative agent of mousepox. Virology 317:165–186.

    PubMed  CAS  Google Scholar 

  44. Handley LM, Mackey JP, Buller RM, Bellone CJ (2006) Orthopoxvirus vaccines and vaccination. In Poxviruses (Mercer A, Schmidt A, Weber O, eds.). Birkhauser Publishing, Basel

    Google Scholar 

  45. Rosenthal SR, Merchlinsky M, Kleppinger C, Goldenthal KL 2001 Developing new smallpox vaccines. Emerg Infect Dis 7:920–926.

    PubMed  CAS  Google Scholar 

  46. Lane JM, Ruben FL, Neff JM, Millar JD 1969 Complications of smallpox vaccination, 1968. N Engl J Med 281:1201–1208.

    PubMed  CAS  Google Scholar 

  47. Lane JM, Ruben FL, Neff JM, Millar JD 1970 Complications of smallpox vaccination, 1968: results of ten statewide surveys. J Infect Dis 122:303–309.

    PubMed  CAS  Google Scholar 

  48. Fulginiti VA, Papier A, Lane JM, Neff JM, Henderson DA 2003 Smallpox vaccination: a review, part II. Adverse events. Clin Infect Dis 37:251–271.

    PubMed  Google Scholar 

  49. Fulginiti VA, Papier A, Lane JM, Neff JM, Henderson DA 2003 Smallpox vaccination: a review, part II. Adverse events Clin Infect Dis 37:251–271.

    Google Scholar 

  50. Cono J, Casey CG, Bell DM 2003 Smallpox vaccination and adverse reactions. Guidance for clinicians. MMWR 52:1–28.

    PubMed  Google Scholar 

  51. Bray M 2003 Pathogenesis and potential antiviral therapy of complications of smallpox vaccination. Antiviral Res 58:101–114.

    PubMed  CAS  Google Scholar 

  52. Rosenthal SR, Merchlinsky M, Kleppinger C, Goldenthal KL 2001 Developing new smallpox vaccines. Emerg Infect Dis 7:920–926.

    PubMed  CAS  Google Scholar 

  53. Kempe CH, Bowles C, Meiklejohn G, Berge TO St, Vincent L, Babu BV, et al 1961 The use of vaccinia hyperimmune gamma-globulin in the prophylaxis of smallpox. Bull World Health Organ 25:41–48.

    PubMed  CAS  Google Scholar 

  54. Mortimer PP 2003 Can postexposure vaccination against smallpox succeed? Clinical Infectious Diseases 36:622–629.

    PubMed  Google Scholar 

  55. Jordan R, Hruby D 2006 Smallpox antiviral drug development: satisfying the animal efficacy rule. Expert Rev Anti Infect Ther 4:277–289.

    PubMed  CAS  Google Scholar 

  56. Painter GR, Buller RML, Huggins J, Moyer RW, Painter W, Doucette M, et al 2006 The challenge of developing an antiviral agent for the treatment of smallpox using the animal efficacy rule. Future Med 1:35–41.

    Google Scholar 

  57. Rosenthal SR, Merchlinsky M, Kleppinger C, Goldenthal KL 2001 Developing new smallpox vaccines. Emerg Infect Dis 7:920–926.

    PubMed  CAS  Google Scholar 

  58. Tulman ER, Delhon G, Afonso CL, Lu Z, Zsak L, Sandybaev NT, et al 2006 Genome of horsepox virus. J Virol 80:9244–9258.

    PubMed  CAS  Google Scholar 

  59. Gordon J, Kovala T, Dales S 1988 Molecular characterization of a prominent antigen of the vaccinia virus envelope. Virology 167:361–369.

    PubMed  CAS  Google Scholar 

  60. Buller RM, Palumbo GJ 1991 Poxvirus pathogenesis. Microbiol Rev 55:80–122.

    PubMed  CAS  Google Scholar 

  61. Fenner F, 1958 The biological characters of several strains of vaccinia, cowpox and rabbitpox viruses. Virology 5:502–529.

    PubMed  CAS  Google Scholar 

  62. Fenner F (1947) Studies in infectious ectromelia of mice. I. Immunization of mice against ectromelia with living vaccinia virus. Aust J Exp Biol Med Sci 25:257–274.

    PubMed  CAS  Google Scholar 

  63. Williamson JD, Reith RW, Jeffrey LJ, Arrand JR, Mackett M 1990 Biological characterization of recombinant vaccinia viruses in mice infected by the respiratory route.[erratum appears in J Gen Virol 1991;72:474]. J Gen Virol 71:2761–2767.

    PubMed  Google Scholar 

  64. Perkus ME, Goebel SJ, Davis SW, Johnson GP, Norton EK, Paoletti E 1991 Deletion of 55 open reading frames from the termini of vaccinia virus. Virology 180:406–410.

    PubMed  CAS  Google Scholar 

  65. Tseng CK, Marquez VE, Fuller RW, Goldstein BM, Haines DR, McPherson H, et al 1989 Synthesis of 3-deazaneplanocin A, a powerful inhibitor of S-adenosylhomocysteine hydrolase with potent and selective in vitro and in vivo antiviral activities. J Med Chem 32:1442–1446.

    PubMed  CAS  Google Scholar 

  66. De Clercq E, Somer P De 1968 Effect of interferon, polyacrylin acid, and polymethacrylic acid on tail lesions on mice infected with vaccinia virus. Appl Microbiol 16:1314–1319.

    PubMed  Google Scholar 

  67. Downie AW (1939) A study of the lesions produced experimentally by cowpox virus. J Pathol 48:361–378.

    Google Scholar 

  68. Gibbs EP, Johnson RH, Collings DF 1973 Cowpox in a dairy herd in the United Kingdom. Vet Rec 92:56–64.

    PubMed  CAS  Google Scholar 

  69. Subrahmanyan TP 1968 A study of the possible basis of age-dependent resistance of mice to poxvirus diseases. Aust J Exp Biol Med Sci 46:251–655.

    PubMed  CAS  Google Scholar 

  70. Mims CA 1968 The response of mice to the intravenous injection of cowpox virus. Br J Exp Pathol 49:24–32.

    PubMed  CAS  Google Scholar 

  71. Bennett M, Crouch AJ, Begon M, Duffy B, Feore S, Gaskell RM, et al 1997 Cowpox in British voles and mice. J Comp Pathol 116:35–44.

    PubMed  CAS  Google Scholar 

  72. Bray M, Martinez M, Smee DF, Kefauver D, Thompson E, Huggins JW 2000 Cidofovir protects mice against lethal aerosol or intranasal cowpox virus challenge. J Infect Dis 181:10–19.

    PubMed  CAS  Google Scholar 

  73. Baker RO, Bray M, Huggins JW 2003 Potential antiviral therapeutics for smallpox, monkeypox and other orthopoxvirus infections. Antiviral Res 57:13–23.

    PubMed  CAS  Google Scholar 

  74. Hooda-DhingraU, Thompson CL, Condit RC1989 Detailed phenotypic characterization of five temperature-sensitive mutants in the 22- and 147-kilodalton subunits of vaccinia virus DNA-dependent RNA polymerase. J Virol 63:714–729.

    Google Scholar 

  75. Martinez MJ, Bray MP, Huggins JW 2000 A mouse model of aerosol-transmitted orthopoxviral disease: morphology of experimental aerosol-transmitted orthopoxviral disease in a cowpox virus-BALB/ c mouse system. Arch Pathol Lab Med 124:362–377.

    PubMed  CAS  Google Scholar 

  76. Buller RML, Fenner F (2007) Mousepox. Fox JG, Barthold SW, Davisson MT, Newcomer CE, Quimby FW, Smith eds.AL, The Mouse in Biomedical Research Elsevier, New York. pp. 67–92.

    Google Scholar 

  77. Buller RM, Palumbo GJ 1991 Poxvirus pathogenesis. Microbiol Rev 55:80–122.

    PubMed  CAS  Google Scholar 

  78. Dick EJ, JrKittell CL, Meyer H, Farrar PL, Ropp SL, Esposito JJ, et al 1996 Mousepox outbreak in a laboratory mouse colony. Lab Anim Sci 46:602–611.

    PubMed  Google Scholar 

  79. Buller RM, Potter M, Wallace GD 1986 Variable resistance to ectromelia (mousepox) virus among genera of Mus. Curr Top Microbiol Immunol 127:319–322.

    PubMed  CAS  Google Scholar 

  80. Surdej P, Jacobs-Lorena M 1994 Strategy for epitope tagging the protein-coding region of any gene. Biotechniques 17:560–565.

    PubMed  CAS  Google Scholar 

  81. Buller RM, Palumbo GJ 1991 Poxvirus pathogenesis. Microbiol Rev 55:80–122.

    PubMed  CAS  Google Scholar 

  82. Fenner F 1948 The pathogenesis of the acute exanthems. An interpretation based on experimental investigations with mousepox (infectious ectromelia of mice). Lancet 11:915–920.

    Google Scholar 

  83. Brownstein DG, Gras L 1995 Chromosome mapping of Rmp-4, a gonad-dependent gene encoding host resistance to mousepox. J Virol 69:6958–6964.

    PubMed  CAS  Google Scholar 

  84. Brownstein DG 1998 Comparative genetics of resistance to viruses. Am J Hum Genet 62:211–214.

    PubMed  CAS  Google Scholar 

  85. Delano ML, Brownstein DG 1995 Innate resistance to lethal mousepox is genetically linked to the NK gene complex on chromosome 6 and correlates with early restriction of virus replication by cells with an NK phenotype. J Virol 69:5875–5877.

    PubMed  CAS  Google Scholar 

  86. Brownstein DG, Gras L 1995 Chromosome mapping of Rmp-4, a gonad-dependent gene encoding host resistance to mousepox. J Virol 69:6958–6964.

    PubMed  CAS  Google Scholar 

  87. Brownstein DG 1998 Comparative genetics of resistance to viruses. Am J Hum Genet 62:211–214.

    PubMed  CAS  Google Scholar 

  88. Roberts JA 1962 Histopathogenesis of mousepox. I. Respiratory infection. Br J Exp Pathol 43:451–461.

    PubMed  CAS  Google Scholar 

  89. Buller RM, Palumbo GJ 1991 Poxvirus pathogenesis. Microbiol Rev 55:80–122.

    PubMed  CAS  Google Scholar 

  90. Greene HSN 1933 A pandemic of rabbit-pox. Pro Soc Exp Biol Med 30:892–894.

    Google Scholar 

  91. Jansen J 1941 Todliche infektionen von kaninchen durch ein filtierbares virus. Zentralbl Bakteriol 148:65–68.

    Google Scholar 

  92. Greene HSN 1934 Rabbit Pox. I. Clinical manifestations and cause of disease. J Exp Med 60:427–440.

    PubMed  CAS  Google Scholar 

  93. Nagaya A, Pogo BG, Dales S 1970 Biogenesis of vaccinia: separation of early stages from maturation by means of rifam-picin. Virology 40:1039–1051.

    PubMed  CAS  Google Scholar 

  94. Li G, Chen N, Roper RL, Feng Z, Hunter A, Danila M et al 2005 Complete coding sequences of the rabbitpox virus genome. J Gen Virol 86:2969–2977.

    PubMed  CAS  Google Scholar 

  95. Westwood JC, Boulter EA, Bowen ET, Maber HB 1966 Experimental respiratory infection with poxviruses. I. Clinical virological and epidemiological studies. Br J Exp Pathol 47:453–465.

    PubMed  CAS  Google Scholar 

  96. Westwood JC, Boulter EA, Bowen ET, Maber HB 1966 Experimental respiratory infection with poxviruses. I. Clinical virological and epidemiological studies. Br J Exp Pathol 47:453–465.

    PubMed  CAS  Google Scholar 

  97. Bedson HS, Duckworth MJ 1963 Rabbit pox: an experimental study of the pathways of infection in rabbits. J Pathol Bacteriol 85:1–21.

    PubMed  CAS  Google Scholar 

  98. Lancaster MC, Boulter EA, Westwood JC, Randles J 1966 Experimental respiratory infection with poxviruses. II. Pathological studies. Br J Exp Pathol 47:466–711.

    PubMed  CAS  Google Scholar 

  99. Westwood JC, Harris WJ, Zwartouw HT, Titmuss DH, Apple-yard G 1964 Studies on the structure of vaccinia virus. J Gen Virol 34:67–78.

    CAS  Google Scholar 

  100. Westwood JC, Boulter EA, Bowen ET, Maber HB 1966 Experimental respiratory infection with poxviruses. I. Clinical virological and epidemiological studies. Br J Exp Pathol 47:453–465.

    PubMed  CAS  Google Scholar 

  101. Downie AW, McCarthy K, Macdonald A, Maccallum FO, Macrae AE 1953 Virus and virus antigen in the blood of smallpox patients; their significance in early diagnosis and prognosis. Lancet 265:164–166.

    PubMed  CAS  Google Scholar 

  102. Westwood JC, Boulter EA, Bowen ET, Maber HB 1966 Experimental respiratory infection with poxviruses. I. Clinical virological and epidemiological studies. Br J Exp Pathol 47:453–465.

    PubMed  CAS  Google Scholar 

  103. Monath TP, Caldwell JR, Mundt W, Fusco J, Johnson CS, Buller M, et al (2004) ACAM2000 clonal Vero cell culture vaccinia virus (New York City Board of Health Strain)-a second-generation smallpox vaccine for biological defense. Int J Infect Dis 8:S31–S44

    PubMed  Google Scholar 

  104. Andersson EC, Christensen JP, Marker O, Thomsen AR 1994 Changes in cell adhesion molecule expression on T cells associated with systemic virus infection. J Immunol 152:1237–1245.

    PubMed  CAS  Google Scholar 

  105. Hahon N, McGavran MH 1961 Air-borne infectivity of the variola-vaccinia group of poxviruses for the cynomolgus monkey, Macaca irus. J Infect Dis 109:294–298.

    PubMed  CAS  Google Scholar 

  106. Zaucha GM, Jahrling PB, Geisbert TW, Swearengen JR, Hensley L 2001 The pathology of experimental aerosolized monkeypox virus infection in cynomolgus monkeys (Macaca fascicularis). Lab Invest 81:1581–1600.

    PubMed  CAS  Google Scholar 

  107. Prier JE, Sauer RM 1958 A pox disease of monkeys. Ann NY Acad Sci 58:951–959.

    Google Scholar 

  108. Westwood JC, Boulter EA, Bowen ET, Maber HB 1966 Experimental respiratory infection with poxviruses. I. Clinical virological and epidemiological studies. Br J Exp Pathol 47:453–465.

    PubMed  CAS  Google Scholar 

  109. Cho CT, Wenner HA 1973 Monkeypox virus. Bacteriol Rev 37:1–18.

    PubMed  CAS  Google Scholar 

  110. Jahrling PB, Hensley LE, Martinez MJ, Leduc JW, Rubins KH, Relman DA, et al 2004 Exploring the potential of variola virus infection of cynomolgus macaques as a model for human smallpox. Proc Natl Acad Sci USA 101:15,196–15,200.

    CAS  Google Scholar 

  111. Breman JG, Henderson DA 2002 Diagnosis and management of smallpox. N Engl J Med 346:1300–1308.

    PubMed  Google Scholar 

  112. Weltzin R, Liu J, Pugachev KV, Myers GA, Coughlin B, Blum PS, et al 2003 Clonal vaccinia virus grown in cell culture as a new smallpox vaccine. Nat Med 9:1125–1130.

    PubMed  CAS  Google Scholar 

  113. Monath TP, Caldwell JR, Mundt W, Fusco J, Johnson CS, Buller M, et al 2004 ACAM2000 clonal Vero cell culture vaccinia virus (New York City Board of Health strain)—a second-generation smallpox vaccine for biological defense. Int J Infect Dis 8:S31–S44.

    PubMed  Google Scholar 

  114. Artenstein AW, Johnson C, Marbury TC, Morrison D, Blum PS, Kemp T, et al 2005 A novel, cell culture-derived smallpox vaccine in vaccinia-naive adults. Vaccine 23:3301–3309.

    PubMed  CAS  Google Scholar 

  115. Poland GA, Grabenstein JD, Neff JM 2005 The US smallpox vaccination program: a review of a large modern era smallpox vaccination implementation program. Vaccine 23:2078–2081.

    PubMed  Google Scholar 

  116. Sutter G, Moss B 1992 Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc Natl Acad Sci USA 89:10,847–10,851.

    CAS  Google Scholar 

  117. Earl PL, Americo JL, Wyatt LS, Eller LA, Whitbeck JC, Cohen GH, et al 2004 Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox. Nature 428:182–185.

    PubMed  CAS  Google Scholar 

  118. Meseda CA, Garcia AD, Kumar A, Mayer AE, Manischewitz J, King LR, et al 2005 Enhanced immunogenicity and protective effect conferred by vaccination with combinations of modified vaccinia virus Ankara and licensed smallpox vaccine Dryvax in a mouse model. Virology 339:164–175.

    PubMed  CAS  Google Scholar 

  119. Staib C, Suezer Y, Kisling S, Kalinke U, Sutter G 2006 Short-term, but not post-exposure, protection against lethal ortho-poxvirus challenge after immunization with modified vaccinia virus Ankara. J Gen Virol 87:2917–2921.

    PubMed  CAS  Google Scholar 

  120. Earl PL, Americo JL, Wyatt LS, Eller LA, Whitbeck JC, Cohen GH, et al 2004 Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox. Nature 428:182–185.

    PubMed  CAS  Google Scholar 

  121. Stittelaar KJ van, Amerongen G, Kondova I, Kuiken T van, Lavieren RF, Pistoor FH, et al 2005 Modified vaccinia virus Ankara protects macaques against respiratory challenge with monkeypox virus. J Virol 79:7845–7851.

    PubMed  CAS  Google Scholar 

  122. Wyatt LS, Earl PL, Eller LA, Moss B 2004 Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge. Proc Natl Acad Sci USA 101:4590–4595.

    PubMed  CAS  Google Scholar 

  123. Parrino J, McCurdy LH, Larkin BD, Gordon IJ, Rucker SE, Enama ME, et al 2007 Safety, immunogenicity and efficacy of modified vaccinia Ankara (MVA) against Dryvax challenge in vaccinia-naive and vaccinia-immune individuals. Vaccine 25:1513–1525.

    PubMed  CAS  Google Scholar 

  124. Vollmar J, Arndtz N, Eckl KM, Thomsen T, Petzold B, Mateo L, et al 2006 Safety and immunogenicity of IMVAMUNE, a promising candidate as a third generation smallpox vaccine. Vaccine 24:2065–2070.

    PubMed  CAS  Google Scholar 

  125. Harrison SC, Alberts B, Ehrenfeld E, Enquist L, Fineberg H, McKnight SL, et al 2004 Discovery of antivirals against smallpox. Proc Natl Acad Sci USA 101:11,178–11,192.

    CAS  Google Scholar 

  126. Carpenter CJ, Arvin AM, Beasley RP, Berns KI, Dolin R, Essex ME, et al (1999) Assessment of Future Scientific Needs for Live Variola Virus. National Academy Press, Washington, D.C.

    Google Scholar 

  127. Painter GR, Hostetler KY 2004 Design and development of oral drugs for the prophylaxis and treatment of smallpox infection. Trends Biotechnol 22:423–427.

    PubMed  CAS  Google Scholar 

  128. Kornbluth RS, Smee DF, Sidwell RW, Snarsky V, Hostetler DH, Evans KY 2006 Mutations in the E9L polymerase gene of cidofovir-resistant vaccinia virus strain WR are associated with the drug resistance phenotype. Antimicrob Agents Che-mother 50:4038–4043.

    CAS  Google Scholar 

  129. Magee WC, Hostetler KY, Evans DH 2005 Mechanism of inhibition of vaccinia virus DNA polymerase by cidofovir diphosphate. Antimicrob Agents Chemother 49:3153–3162.

    PubMed  CAS  Google Scholar 

  130. Hostetler KY (2007) Synthesis and antiviral evaluation of broad spectrum, orally avtive analogs of cidofovir and other acyclic nucleoside phosphonates. In Advances in Antiviral Drug Design (De Clercq E, ed.).

    Google Scholar 

  131. Yang G, Pevear DC, Davies MH, Collett MS, Bailey T, Rippen S, et al 2005 An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus Challenge. J Virol 79:13,139–13,149.

    CAS  Google Scholar 

  132. Quenelle DC, Buller RM, Parker S, Keith KA, Hruby DE, Jordan R, et al 2007 Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice. Antimicrob Agents Chemother 51:689–695

    PubMed  CAS  Google Scholar 

  133. Breman JG, Henderson DA 2002 Diagnosis and management of smallpox. N Engl J Med 346:1300–1308. Mark Buller, Lauren Han dley and Scott Parker

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Molecular Microbiology and Immunology, Saint Louis University Health Sciences Center, St. Louis, MO, USA

    Mark Buller, Lauren Handley & Scott Parker

Authors
  1. Mark Buller
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lauren Handley
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Scott Parker
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Vassil St. Georgiev PhD Karl A. Western MD John J. McGowan PhD

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Humana Press, a part of Springer Science+Business Media, LLC

About this paper

Cite this paper

Buller, M., Handley, L., Parker, S. (2008). Development of Prophylactics and Therapeutics Against the Smallpox and Monkeypox Biothreat Agents. In: Georgiev, V.S., Western, K.A., McGowan, J.J. (eds) National Institute of Allergy and Infectious Diseases, NIH. Infectious Disease. Humana Press. https://doi.org/10.1007/978-1-59745-569-5_17

Download citation

Publish with us

Policies and ethics

Search

Navigation